Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: Retrospective analysis of a multicenter study

Journal of B.U.ON.

Volumn 17, Issue 1, 2012, Pages 102-105

  Inal, Ali ^a   Kos, F T ^b   Algin, E ^c   Yildiz, R ^d   Berk, V ^e   Tugba Unek, I ^f   Colak, D ^g   Kucukoner, M ^a   Tamer Elkiran, E ^h   Helvaci, K ⁱ   Geredeli, C ^j   Dane, F ^k   Balakan, O ^l   Ali Kaplan, M ^a   Gok Durnali, A ⁱ   Harputoglu, H ^m   Goksel, G ⁿ   Ozdemir, N ^b   Buyukberber, S ^c   Gumus, M ^d   Ozkan, M ^e   Benekli, M ^c   Isikdogan, A ^a   more..

^a DICLE UNIVERSITY   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c GAZI UNIVERSITY   (Turkey)

^d DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^e ERCIYES UNIVERSITY   (Turkey)

^f DOKUZ EYLUL UNIVERSITY   (Turkey)

^g DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

^h FIRAT UNIVERSITY   (Turkey)

ⁱ Dr Abdurrahman Yurtaslan Education and Research Hospital   (Turkey)

^j Secuk University   (Turkey)

^k MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^l GAZIANTEP UNIVERSITY   (Turkey)

^m INONU UNIVERSITY   (Turkey)

ⁿ CELAL BAYAR UNIVERSITY   (Turkey)

more..

Author keywords

Cancer; Gemcitabine; Pancreas; Prognosis

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHOLESTASIS; FEMALE; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS RESECTION; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84859823703     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Jemal A, Siegel R, Ward E et al. Cancer Statistics, 2008. CA Cancer J Clin 2008; 58: 71-96. (Pubitemid 351521864)
2. Evans DB, Abbruzzese JL, Willett CG. Cancer of the pancreas. In: DeVita VT, Hellman S, Rosenberg SA (Eds): Cancer - Principles and Practice of Oncology (6th Edn). Philadelphia: Lippincott and Wilkins, 2001, pp 1126-1161.
3. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004; 363: 1049-1057. (Pubitemid 38410779)
4. Oztop I, Alacacioglu A, Unek IT et al. Gemcitabine plus infusional 5-fluorouracil and high dose leucovorin in advanced stage pancreatic cancer. J BUON 2010; 15: 462-469.
5. National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology: Pancreatic adenocarcinoma version 1.2009. Fort Washington, PA, National Comprehensive Cancer Network, 2009.
6. Heinemann V, Labianca R, Hinke A et al. Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: Pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol 2007; 18: 1652-1659. (Pubitemid 47514482)
7. Heinemann V, Quietzsch D, Gieseler F et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24: 3946-3952. (Pubitemid 46630743)
8. Viret F, Ychou M, Lepille D et al. Gemcitabine in combination with cisplatin versus gemcitabine alone in the treatment of locally advanced or metastatic pancreatic cancer: final results of a multicenter randomized phase II study. Proc Am Soc Clin Oncol 2004: 22 (abstr 4118).
9. Colucci G, Giuliani F, Gebbia V et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase HI study of the Gruppo Oncologico dell'Italia Meridionale. Cancer 2002; 94: 902-910. (Pubitemid 34150843)
10. Papadoniou N, Kosmas C, Gennatas K et al. Prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis. Anticancer Res 2008; 28: 543-549. (Pubitemid 351362868)
11. Shimoda M, Katoh M, Kita J, Sawada T, Kubota K. The Glasgow Prognostic Score is a good predictor of treatment outcome in patients with unresectable pancreatic cancer. Chemotherapy 2010; 56: 501-506.
12. Engelken FJ, Bettschart V, Rahman MQ, Parks RW, Garden OJ. Prognostic factors in the palliation of pancreatic cancer. Eur J Surg Oncol 2003; 29: 368-373. (Pubitemid 36675694)
13. Ikeda M, Okada S, Tokuuye K, Ueno H, Okusaka T. Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer 2001; 91: 490-495. (Pubitemid 32105694)
14. Ueno H, Okada S, Okusaka T, Ikeda M. Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 2000; 59: 296-301.
15. Tsavaris N, Kosmas C, Papadoniou N et al. CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis. J Chemother 2009; 21: 673-680.
16. Eyigor C, Karaca B, Kuzeyli-Yildirim Y, Uslu R, Uyar M, Coker A. Does the tumor localization in advanced pancreatic cancer have an influence on the management of symptoms and pain? J BUON 2010; 15: 543-546.
17. Marechal R, Demols A, Gay F et al. Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer. Oncology 2007; 73: 41-51. (Pubitemid 351465599)
18. Sawaki A, Kanemitsu Y, Mizuno N et al. Practical prognostic index for patients with metastatic pancreatic cancer treated with gemcitabine. J Gastroenterol Hepatol 2008; 23(8 Pt 1): 1292-1297.
19. Tanaka T, Ikeda M, Okusaka T et al. Prognostic factors in Japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy. Jpn J Clin Oncol 2008; 38: 755-761.
20. Nakai Y, Kawabe T, Isayama H et al. CA 19-9 response as an early indicator of the effectiveness of gemcitabine in patients with advanced pancreatic cancer. Oncology 2008; 75: 120-126.
21. Saad ED, Machado MC, Wajsbrot D et al. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Intern J Gastrointest Cancer 2002; 32: 35-41. (Pubitemid 36323101)